Antitumor Potential of Sericite Treatment Mediated by Cell Cycle Arrest in Triple-Negative MDA-MB231 Breast Cancer Cells
Open Access
- 25 September 2022
- journal article
- research article
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-14
Abstract
Breast cancer is the most common cancer and the leading cause of cancer-related mortality among females worldwide. Triple-negative breast cancer (TNBC) accounts for about 1015 of all breast cancers and is usually more aggressive and has a poorer prognosis. Sericite has been known to have antitumor and immune-stimulatory effects. Although the chemopreventive potential of sericite has been demonstrated in other cancers, its molecular pathways in TNBC still require investigation. Thus, in the present study, the antitumor mechanism of sericite against MDA-MB231 breast cancer cells was examined in vitro and in an in vivo xenograft mouse model. Sericite treatment reduced cell proliferation and cell proliferation marker proliferating cell nuclear antigen (PCNA) in MDA-MB231 cells. It also decreased the total cell number and arrested cells in the G0/G1 phase of the cell cycle with an increase in the phosphorylation of P53 and upregulation of cell cycle regulatory proteins P21 and P16. In addition, sericite treatment also induced apoptosis signaling, which was evident by the upregulation of apoptotic protein markers cleaved caspases 3 and 9. A reduction in reactive oxygen species (ROS), NADPH oxidase 4 (NOX4), p22phox, and heat shock proteins (HSPs) was also observed. Similar results were obtained in vivo with significantly reduced tumor volume in sericite-administered mice. Collectively, these findings suggest that sericite has antitumor potential based on its property to induce cell cycle arrest and apoptotic cell death and therefore could serve as a potential therapeutic agent and crucial candidate in anticancer drug development for TNBC.Keywords
Funding Information
- Ministry of Education, South Korea (NRF-2014R1A6A1029617, NRF-2019R1I1A3A0105949712)
- Chungnam National University (NRF-2014R1A6A1029617, NRF-2019R1I1A3A0105949712)
- Jowin Corp (NRF-2014R1A6A1029617, NRF-2019R1I1A3A0105949712)
This publication has 32 references indexed in Scilit:
- Particled Mica, STB-HO has chemopreventive potential via G1 arrest, and inhibition of proliferation and vascular endothelial growth factor receptor 2 in HCT colorectal cancer cellsBMC Complementary and Alternative Medicine, 2013
- Arsenic Trioxide Inhibits Cell Growth and Induces Apoptosis through Inactivation of Notch Signaling Pathway in Breast CancerInternational Journal of Molecular Sciences, 2012
- Novel role of p66Shc in ROS-dependent VEGF signaling and angiogenesis in endothelial cellsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of a far infrared-emitting sericite belt in patients with primary dysmenorrheaComplementary Therapies in Medicine, 2011
- Toxicological Studies of “Chondrokola rosh”, an Ayurvedic Preparation on Liver Function Tests of RatsAfrican Journal of Traditional, Complementary and Alternative Medicines, 2011
- Dietary aluminosilicate supplement enhances immune activity in mice and reinforces clearance of porcine circovirus type 2 in experimentally infected pigsVeterinary Microbiology, 2010
- Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patientsCancer, 2007
- Cadmium induces mitogenic signaling in breast cancer cell by an ERα-dependent mechanismMolecular and Cellular Endocrinology, 2007
- Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implicationsCell Stress and Chaperones, 2005
- The p66shc Protein: A Mediator of the Programmed Death of an Organism?IUBMB Life, 2000